Peter Hébert

Background

Peter Hébert is a Partner and Co-Founder of Lux Capital, the deep-tech venture capital firm he co-founded in 2000 with Josh Wolfe and Robert Paull ¹². The firm was launched in March 2000, just as the dot-com bubble was about to burst ³.

Hébert began his career at Lehman Brothers, where he worked in the firm’s top-ranked Equity Research group ¹. He was a Chancellor’s Scholar and graduated cum laude from Syracuse University’s Newhouse School, where he was also the founding president of Syracuse’s first venture organization, Future Business Leaders and Entrepreneurs ¹.

In 2003, Hébert led the spin-off of Lux Research from Lux Capital and, as founding CEO, helped build it into the leading emerging-technology research firm before it was acquired by Bregal Sagemount ¹⁴. Hébert also co-founded Thematic in 2021, a next-generation index and ETF developer ¹. He created the Nasdaq Lux Health Tech Index (NASDAQ: NQHTEC) and helped launch the First Trust Nasdaq Lux Digital Health Solutions ETF (NASDAQ: EKG) ¹⁵.

Hébert has appeared on CNBC and Bloomberg TV and has spoken at Columbia, Cornell, MIT, Stanford, Yale, and the National Science Foundation ¹. He serves on the board of the Boys & Girls Club of the Peninsula ¹.

Stated Thesis

Hébert co-founded Lux Capital on the principle that “in order to have the biggest impact on the future, one should support the most scientifically and technologically ambitious ventures” ¹. He seeks founders developing breakthrough innovations — things most considered impossible — that, if successful, would become fundamental to society ¹.

On health tech specifically, Hébert has stated: “The most compelling invention and innovation occurs at the edges of multiple technical disciplines” ⁵. He has described Lux’s approach as deliberately working outside the unspoken medtech industry rule to “stay in your swim lane,” instead embracing “the most cutting edge, multi-disciplinary technologies Silicon Valley has to offer: AI & machine learning, robotics and automation, and machine vision” ⁵.

On the broader health tech opportunity, he has written: “The marriage between healthcare and technology will impact everything: how patients interact with care providers; how diagnostic data is obtained and analyzed; how intervention is recommended and performed; and how outcomes are measured and quantified” ⁵.

The early days of Lux were characterized by deliberate contrarianism. As Hébert told Newcomer: “Ignored, obscure, obscure, obscure, and then all of a sudden, there’s more significant interest over the last five years” ³. On early validation, referring to the Kurion nuclear waste disposal exit: “So that was the first time that I think people thought, wow, you know, some of these obscure areas, deep science can pay off” ³.

Inferred Thesis

Based on 22 verified investments personally attributed to Hébert, the following patterns emerge. Note: Lux Capital has approximately 287 portfolio organizations ⁶, and Hébert’s personal portfolio represents a subset.

Sector distribution (22 verified personal investments): - Healthcare/biotech/medtech: 8 of 22 (36%) — Auris Health, Mendaera, Carbon Health, eGenesis, Adimab, Bright Machines (healthcare automation), Vium, Matterport (3D mapping used in healthcare) - Hardware/semiconductors: 5 of 22 (23%) — Everspin Technologies, Luxtera, SiBEAM, Flex Logix, Transphorm - Energy/cleantech: 2 of 22 (9%) — Gridco Systems, Accelergy - Technology/data: 3 of 22 (14%) — Lux Research, Thematic, Ripcord - Maritime/agriculture: 2 of 22 (9%) — Saildrone, Vosbor - Other: 2 of 22 (9%) — Perchwell, Ingenuity

Stage distribution: Hébert invests across seed through growth stages, consistent with Lux’s broad investment range of $100K to $100M ². His most prominent exits (Auris Health, Luxtera, Matterport) were all early-stage bets held for extended periods.

Geographic focus: Primarily US-based companies, concentrated in the San Francisco Bay Area and New York ¹².

Investment conviction pattern: Hébert’s most notable characteristic is deep, concentrated conviction. In the case of Auris Health, Lux invested nearly $50 million — the largest allocation of capital across their 120+ portfolio companies at the time — and held through periods when the company struggled to raise follow-on funding ⁷. This “conviction investing” style favors a smaller number of high-conviction bets over portfolio diversification.

Notable pattern vs. stated thesis: While Lux broadly positions itself as a “science and technology” firm, Hébert’s personal portfolio is heavily tilted toward healthcare/medtech (36%) and physical hardware (23%), reflecting his role as the firm’s healthcare and hardware specialist, complementing co-founder Josh Wolfe’s focus on defense and AI.

Portfolio

This table represents approximately 22 of Hébert’s verified personal investments. Years marked with ~ are approximate based on available data. Lux Capital’s total portfolio spans ~287 organizations ⁶.

In Their Own Words

“The most compelling invention and innovation occurs at the edges of multiple technical disciplines.” — Peter Hébert, Lux Capital blog ⁵

“The marriage between healthcare and technology will impact everything: how patients interact with care providers; how diagnostic data is obtained and analyzed; how intervention is recommended and performed; and how outcomes are measured and quantified.” — Peter Hébert, Lux Capital blog ⁵

“Ignored, obscure, obscure, obscure, and then all of a sudden, there’s more significant interest over the last five years.” — Peter Hébert, Newcomer interview ³

“So that was the first time that I think people thought, wow, you know, some of these obscure areas, deep science can pay off.” — Peter Hébert, on Kurion exit, Newcomer interview ³

“We’ll be there to back those visionary founders at every step of the way.” — Peter Hébert, Lux Capital blog ⁵

What Founders Say

No independently sourced founder testimonials found. While Lux Capital’s portfolio founders have spoken positively about the firm’s hands-on approach in firm-level marketing materials, specific verified quotes from founders about working with Peter Hébert personally could not be independently confirmed at this time.

Sources